{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,9,16]],"date-time":"2023-09-16T23:39:34Z","timestamp":1694907574567},"reference-count":22,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2015,1]]},"DOI":"10.1097\/ajp.0000000000000082","type":"journal-article","created":{"date-parts":[[2014,2,12]],"date-time":"2014-02-12T18:44:29Z","timestamp":1392230669000},"page":"58-65","source":"Crossref","is-referenced-by-count":7,"title":["Real-world Experience With Once-daily Gabapentin for the Treatment of Postherpetic Neuralgia (PHN)"],"prefix":"10.1097","volume":"31","author":[{"given":"Herbert G.","family":"Markley","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edwin D.","family":"Dunteman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephanie","family":"Kareht","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Sweeney","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-9-20210204","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/0304-3959(96)03122-3","article-title":"Pain and its persistence in herpes zoster.","volume":"67","author":"Dworkin","year":"1996","journal-title":"Pain"},{"key":"R2-9-20210204","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/S0304-3959(01)00407-9","article-title":"Postherpetic Neuralgia Study Group. Gabapentin in postherpetic neuralgia: a randomised, double blind, placebo controlled study.","volume":"94","author":"Rice","year":"2001","journal-title":"Pain"},{"key":"R3-9-20210204","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1001\/jama.280.21.1837","article-title":". Gabapentin for the treatment of postherpetic neuralgia: a randomized controlled trial.","volume":"280","author":"Rowbotham","year":"1998","journal-title":"JAMA"},{"key":"R4-9-20210204","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.4065\/mcp.2009.0649","article-title":". Recommendations for the pharmacological management of neuropathic pain: an overview and literature update.","volume":"85","author":"Dworkin","year":"2010","journal-title":"Mayo Clin Proc"},{"key":"R5-9-20210204","doi-asserted-by":"crossref","first-page":"409","DOI":"10.2165\/00003495-199346030-00007","article-title":"Gabapentin. A review of its pharmacological properties and clinical potential in epilepsy.","volume":"46","author":"Goa","year":"1993","journal-title":"Drugs"},{"key":"R6-9-20210204","first-page":"613","article-title":"Clinical pharmacokinetics of gabapentin.","volume":"318","author":"Bockbrader","year":"1995","journal-title":"Drugs Today"},{"key":"R7-9-20210204","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1023\/A:1018951214146","article-title":". A saturable transport mechanism in the intestinal absorption of gabapentin is the underlying cause of the lack of proportionality between increasing dose and drug levels in plasma.","volume":"10","author":"Stewart","year":"1993","journal-title":"Pharm Res"},{"key":"R8-9-20210204","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1177\/0091270010368411","article-title":"Pharmacokinetics of gabapentin in a novel gastric-retentive extended-release formulation: comparison with an immediate-release formulation and effect of dose escalation and food.","volume":"51","author":"Chen","year":"2011","journal-title":"J Clin Pharmacol"},{"key":"R9-9-20210204","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1097\/AJP.0b013e318258993e","article-title":"Investigators D-S. Gastroretentive gabapentin (G-GR) formulation reduces intensity of pain associated with postherpetic neuralgia (PHN).","volume":"29","author":"Sang","year":"2012","journal-title":"Clin J Pain"},{"key":"R10-9-20210204","doi-asserted-by":"crossref","first-page":"765","DOI":"10.2165\/11539520-000000000-00000","article-title":"Gabapentin extended-release tablets for the treatment of patients with postherpetic neuralgia: a randomized, double-blind, placebo-controlled, multicentre study.","volume":"30","author":"Wallace","year":"2010","journal-title":"Clin Drug Investig"},{"key":"R11-9-20210204","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.jpainsymman.2012.07.011","article-title":". Once-daily gastroretentive gabapentin for postherpetic neuralgia: integrated efficacy, time to onset of pain relief and safety analyses of data from two phase 3 multicenter, randomized, double-blind, placebo-controlled studies.","volume":"46","author":"Rauck","year":"2013","journal-title":"J Pain Symptom Manage"},{"key":"R12-9-20210204","first-page":"203","article-title":"Tolerability and safety of gastroretentive once-daily gabapentin tablets for the treatment of postherpetic neuralgia.","volume":"5","author":"Irving","year":"2012","journal-title":"J Pain Res"},{"key":"R15-9-20210204","doi-asserted-by":"crossref","first-page":"637","DOI":"10.2147\/CIA.S1939","article-title":"Pharmacological pain management in the elderly patient.","volume":"2","author":"McCleane","year":"2007","journal-title":"Clin Interv Aging"},{"key":"R16-9-20210204","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1097\/AJP.0b013e3181934276","article-title":". Efficacy and tolerability of gastric-retentive gabapentin for the treatment of postherpetic neuralgia: results of a double-blind, randomized, placebo-controlled clinical trial.","volume":"25","author":"Irving","year":"2009","journal-title":"Clin J Pain"},{"key":"R17-9-20210204","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1016\/S0149-2918(01)80109-0","article-title":"A systematic review of the associations between dose regimens and medication compliance.","volume":"23","author":"Claxton","year":"2001","journal-title":"Clin Ther"},{"key":"R18-9-20210204","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1185\/030079906X80404","article-title":". Efficacy and tolerability of twice-daily pregabalin for treating pain and related sleep interference in postherpetic neuralgia: a 13-week, randomized trial.","volume":"22","author":"van Seventer","year":"2006","journal-title":"Curr Med Res Opin"},{"key":"R19-9-20210204","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.pain.2004.01.001","article-title":". Pregabalin reduces pain and improves sleep and mood disturbances in patients with post-herpetic neuralgia: results of a randomised, placebo-controlled clinical trial.","volume":"109","author":"Sabatowski","year":"2004","journal-title":"Pain"},{"key":"R20-9-20210204","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.pain.2005.10.007","article-title":". Chronobiological characteristics of painful diabetic neuropathy and postherpetic neuralgia: diurnal pain variation and effects of analgesic therapy.","volume":"120","author":"Odrcich","year":"2006","journal-title":"Pain"},{"key":"R21-9-20210204","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.smrv.2005.08.001","article-title":"Sleep deprivation and pain perception.","volume":"10","author":"Lautenbacher","year":"2006","journal-title":"Sleep Med Rev"},{"key":"R22-9-20210204","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.pain.2008.01.025","article-title":". Duration of sleep contributes to next-day pain report in the general population.","volume":"137","author":"Edwards","year":"2008","journal-title":"Pain"},{"key":"R23-9-20210204","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1016\/j.clinthera.2008.05.008","article-title":". Pharmacokinetics of gabapentin after a single day and at steady state following the administration of gastric-retentive, extended-release, and immediate-release tablets: a randomized, open-label, multiple-dose, three-way crossover, exploratory study in healthy subjects.","volume":"30","author":"Gordi","year":"2008","journal-title":"Clin Ther"},{"key":"R24-9-20210204","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1517\/17425247.2012.709231","article-title":"Clinical development of a once daily gastroretentive formulation of gabapentin for treatment of postherpetic neuralgia: an overview.","volume":"9","author":"Argoff","year":"2012","journal-title":"Expert Opin Drug Deliv"}],"container-title":["The Clinical Journal of Pain"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/AJP.0000000000000082","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,13]],"date-time":"2021-05-13T22:18:39Z","timestamp":1620944319000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00002508-201501000-00009"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,1]]},"references-count":22,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015]]}},"URL":"https:\/\/doi.org\/10.1097\/ajp.0000000000000082","relation":{},"ISSN":["0749-8047"],"issn-type":[{"value":"0749-8047","type":"print"}],"subject":[],"published":{"date-parts":[[2015,1]]}}}